Loading...
Header Logo
Keywords
Last Name
Institution

LIANG ZHANG

TitleAssistant Professor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980. PMID: 29666304.
      View in: PubMed
    2. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45. PMID: 26059948.
      View in: PubMed
    3. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25214559.
      View in: PubMed
    4. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41. PMID: 24886772.
      View in: PubMed
    5. Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93. PMID: 24611650.
      View in: PubMed
    6. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56. PMID: 24375125.
      View in: PubMed
    7. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504. PMID: 23990113.
      View in: PubMed
    8. Axelrod M, Ou Z, Brett LK, Zhang L, Lopez ER, Tamayo AT, Gordon V, Ford RJ, Williams ME, Pham LV, Weber MJ, Wang ML. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014 Feb; 28(2):407-10. PMID: 23979520.
      View in: PubMed
    9. Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013 Aug 02; 6:55. PMID: 23915913.
      View in: PubMed
    10. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16. PMID: 23782157.
      View in: PubMed
    11. Zhang L, Newberry KJ, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol. 2013 Jun; 9(6):495-7. PMID: 23730878.
      View in: PubMed
    12. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      View in: PubMed
    13. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4. PMID: 22986101.
      View in: PubMed
    14. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92. PMID: 22968454.
      View in: PubMed
    15. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      View in: PubMed
    16. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl). 2012 Jun; 90(6):695-706. PMID: 22207485.
      View in: PubMed
    17. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8. PMID: 22000823.
      View in: PubMed
    18. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011 Mar 26; 71(5):625-49. PMID: 21443285.
      View in: PubMed
    19. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6. PMID: 21047686.
      View in: PubMed
    20. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep; 84(9):553-9. PMID: 19565649.
      View in: PubMed
    21. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9. PMID: 19654406.
      View in: PubMed
    22. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Cai Z, Yi Q. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009 Jul; 23(7):1320-8. PMID: 19225534.
      View in: PubMed
    23. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60. PMID: 18381957.
      View in: PubMed
    24. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008 Feb; 83(2):144-9. PMID: 17722077.
      View in: PubMed
    25. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85. PMID: 17898787.
      View in: PubMed
    26. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Oct 15; 110(8):3028-35. PMID: 17644731.
      View in: PubMed
    27. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94. PMID: 17515399.
      View in: PubMed
    28. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62. PMID: 17317853.
      View in: PubMed
    29. Wu S, Guo W, Teraishi F, Pang J, Kaluarachchi K, Zhang L, Davis J, Dong F, Yan B, Fang B. Anticancer activity of 5-benzylidene-2-phenylimino-1, 3-thiazolidin-4-one (BPT) analogs. Med Chem. 2006 Nov; 2(6):597-605. PMID: 17105441.
      View in: PubMed
    30. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jul; 6(7):983-91. PMID: 16831071.
      View in: PubMed
    31. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther. 2002 Oct; 9(20):1379-86. PMID: 12365003.
      View in: PubMed
    32. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther. 2002 Sep; 9(18):1262-70. PMID: 12215894.
      View in: PubMed
    33. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy. Chinese Journal of Cancer. 34.
    34. CD4+ T cells play a crucial role for lenalidomide in vivo antitumor activity in murine multiple myeloma. Oncotarget. 6:36032-36040.
    35. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. Archiv der Pharmazie. 349:356-362.
    36. Lenalidomide in relapsed or refractory mantle cell lymphoma. Therapeutic Advances in Hematology. 5:91-101.
    37. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. OncoImmunology. 5.
    ZHANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description